Combination Therapy in Androgenetic Alopecia: A Network Meta-Analysis of Minoxidil and Other Pharmacological Agents

This study found that platelet-rich plasma therapy may be a useful alternative to 5% topical minoxidil for treating androgenetic alopecia, with differences in the effectiveness and patient satisfaction outcomes observed.

This review highlights potential therapeutic mechanisms of natural products for androgenetic alopecia, suggesting they may modulate signaling pathways and have anti-inflammatory and antioxidant effects.

In this study, a combination of 5% minoxidil lotion and 0.25% topical finasteride spray significantly increased hair density and improved photographic assessments in men with androgenetic alopecia compared to the treatments used alone, with all methods showing good tolerability.

This study found that combining minoxidil and spironolactone was more effective for hair density and severity of hair loss in women with androgenic alopecia compared to minoxidil and finasteride, with no serious adverse effects reported.

This source highlights new developments in treating androgenetic alopecia, including low-dose oral minoxidil and advancements in photobiomodulation, platelet-rich plasma, and hair transplantation techniques, providing clinicians with more options.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This prospective randomized controlled trial found that combining platelet-rich plasma plus basic fibroblast growth factor injections with topical minoxidil significantly improves hair count and growth rate in androgenetic alopecia patients compared to either treatment alone.

This review examines the efficacy of various novel treatments for androgenetic alopecia, including oral minoxidil and platelet-rich plasma, suggesting potential benefits but emphasizing the need for further high-quality clinical trials to thoroughly evaluate their effectiveness.

This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.

This study concluded that both oral and topical spironolactone effectively treat androgenetic alopecia, with topical administration being safer and suitable for any gender, especially when combined with minoxidil.

In this study, both platelet-rich plasma and minoxidil increased hair counts and density in moderate androgenetic alopecia in men, but patient satisfaction was higher with minoxidil, which also had fewer side effects.

This review reports on new and effective drug developments for treating severe alopecia areata, including oral baricitinib, but emphasizes that no treatment guarantees permanent remission or works for all patients, with high recurrence rates after stopping medication.

This study found that combining 5% topical minoxidil and 5% topical spironolactone solutions may enhance treatment efficacy for androgenetic alopecia in both men and women, with significant reductions in vellus hair.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

In this study, a combination treatment of topical 2% flutamide and 5% minoxidil significantly improved hair density, hair thickness, and patient satisfaction more than 5% minoxidil alone in patients with androgenetic alopecia over six months.

This study found that adding platelet-rich plasma to 5% minoxidil treatment improved hair growth outcomes in patients with androgenetic alopecia compared to minoxidil alone.

This study found that in the treatment of androgenetic alopecia, combination therapies involving topical and systemic treatments with adjunctive therapy demonstrated the highest efficacy in improving hair density and diameter compared to placebo, based on a network meta-analysis of 49 randomized controlled trials.

This review discusses treatment options for androgenetic alopecia in transgender and gender-diverse patients, highlighting first-line treatments like topical minoxidil and finasteride, but reports no new clinical results.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

In this study, ALRV5XR treatment significantly increased terminal hair density in men with androgenetic alopecia after 24 weeks, while also decreasing vellus hair density, and was well tolerated without adverse events, suggesting its potential efficacy over standard therapies.

This study found that while both cetirizine 1% and minoxidil 5% increased hair density in men with androgenetic alopecia, minoxidil showed a significantly higher improvement, and both treatments lost effectiveness after 8 weeks without use; cetirizine was well-tolerated with no significant adverse reactions.

This study found that increased levels of PGD2 and prostacyclin and decreased levels of PGE2 and PGF2α were associated with baldness in androgenetic alopecia, suggesting potential targets for treatment.

This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.

This pilot study found that platelet-rich plasma injections did not improve hair growth in men with androgenetic alopecia.

This article discusses the potential for topical caffeine as a natural alternative for treating androgenetic alopecia due to its ability to penetrate skin, but it reports no new clinical findings.

This review discusses female androgenetic alopecia, highlighting its diagnostic challenges and management strategies, but it reports no new results.

This study found that 5% topical minoxidil was moderately more effective at increasing hair regrowth than 10% minoxidil and placebo in men with androgenetic alopecia.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This review discusses advances in molecular biology and genetics related to androgenetic alopecia and reports no new clinical results.

This study found that JetPeel-assisted topical minoxidil significantly improved hair growth in patients with androgenetic alopecia compared to topical minoxidil alone or no treatment.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.

In this study of men with androgenetic alopecia, dutasteride was shown to be more effective than finasteride in increasing hair count and reversing hair miniaturization over 24 weeks, with both treatments displaying similar side effect profiles.

This study found that platelet-rich plasma significantly increased hair density and anagen hair proportions in androgenetic alopecia patients, suggesting potential as an adjuvant therapy.

This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.

This study found that 5% minoxidil topical foam was effective in stabilizing hair density and scalp coverage in men with moderate androgenetic alopecia over 104 weeks, with good safety and tolerability.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

This study found that topical valproic acid significantly increased hair count in male patients with moderate androgenetic alopecia compared to placebo over 24 weeks.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.

This study concluded that a combined once-daily solution of 5% minoxidil and 0.01% tretinoin is as effective and safe as the conventional twice-daily 5% minoxidil application for treating androgenetic alopecia in men.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.